Comanche Biopharma
PrivateLast Round
VC Round
Jan 5, 2026
Total Funding Raised
$111.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Comanche Biopharma Comparables
Compare Comanche Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MirZyme Therapeutics | 86% | |
| DiaMedica Therapeutics Inc. | 67% | |
| Evergreen Therapeutics, Inc. | 63% |
Comanche Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 5, 2026 | ||||
| Series B | Jan 17, 2024 | ||||
| Series A | Jun 28, 2021 |
Key People
Founding team and executive leadership
Comanche Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series A, VC Round, Series B |
| New Enterprise Associates (NEA) | VC Round, Series B |
| F-Prime Capital | Series A, Series B |
| Longview Healthcare Ventures | Series A, VC Round, Series B |
| F-Prime Capital | VC Round, Series B, Series A |
| Lilly Asia Ventures | Series A, VC Round, Series B |
| Atlas Venture | VC Round, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 7, 2026
Open roles increased to 10, doubling the trailing average.
- Aug 22, 2026
Monthly visitors grew 72% MoM, reaching 3K.
Comanche Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Comanche Biopharma's valuation, stock price, and market status.
Is Comanche a public or private company?
Comanche is a private company.
What is the current stock price of Comanche?
Comanche is a private company with no public stock price. No recent secondary market data is available.
How much is Comanche worth (valuation)?
Valuation information for Comanche is not publicly available.
Can I buy Comanche stock?
Comanche shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Comanche's last funding round?
Comanche's most recent funding round was Series B on January 17, 2024.
Who are the main investors in Comanche?
Key investors in Comanche include New Enterprise Associates (NEA).
Will Comanche IPO soon?
No public IPO plans have been announced for Comanche.
How can I track Comanche secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Comanche's secondary market activity and sign up for updates.